While MITF expression does not seem to be relevant in this melanoma cell population, both WNT5A and AXL expressions correlate with clinical response and therapy resistance, suggesting that assessing the AXL/WNT5A expression status could be used as prognostic and/or predictive marker. Here, WNT5A is linked to melanoma.